Navigation Links
Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
Date:8/16/2010

Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets -- LAIYANG, China, Aug. 16 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services Click to view news release full screen  

Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets

 

LAIYANG, China, Aug. 16 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (Nasdaq: JGBO) (the "Company" or "Jiangbo"), today announced that the Company received approval from the Shandong Food and Drug Administration ("Shandong FDA") to start the sales of Felodipine sustained release ("SR") tablets.

After the Company received approval from the Chinese State Food and Drug Administration ("SFDA") to start producing Felodipine SR tablets in early June this year, Shandong FDA reviewed the Company's manufacturing equipment and capacity to produce Felodipine SR tablets, examined the final products from its pilot production and approved the sale of Felodipine SR tablets. Felodipine SR is a well recognized generic drug to treat hypertension and is listed in China's Basic Medical Insurance Catalog for medical coverage.

As the current market leader recently increased the selling price of its Felodipine SR tablets, many of its distributors have turned to Jiangbo and expressed their interest in building a cooperative relationship. Jiangbo has engaged ten major distributors to sell this product in a number of different regions throughout China and believes that its strong distribution network will enable it to expand its market share in Felodipine SR tablets, quickly.

"We are very excited to begin the commercial launch of Felodipine SR tablets, which we believe will be a key revenue and profit growth driver for us in the next few years. We estimate revenue potential for this drug to be between $8 million and $12 million in the first twelve months of launch with a projected gross margin of at least 70%," said Mr. Linxian Jin, CEO of Jiangbo. "We believe the addition of Felodipine SR tablets will enrich our product portfolio and will strengthen our competitive market position, while providing more cost effective new medicine to meet growing patient demand."

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( http://www.jiangbopharma.com ).

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to execute its strategic plan. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact: Jiangbo Pharmaceuticals, Inc. Ms. Elsa Sung, CFO Phone: +1-954-903-9378 x2 Email: elsasung@jiangbo.com Web: http:// www.jiangbopharma.com CCG Investor Relations Mr. Crocker Coulson, President Phone: +1-646-213-1915 Email: crocker.coulson@ccgir.com Web: http://www.ccgirasia.com
'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
2. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
3. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
4. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
5. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
6. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
7. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
8. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
9. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
10. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
11. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  BERG, ... a data-driven, biological research approach, today announced ... to the discovery of new data using ... facilitate brown fat metabolism. Joslin Diabetes Center ... Interrogative Biology® platform for analysis of samples.  ...
(Date:3/27/2017)... -- Twist Bioscience, a company accelerating science and innovation through ... an additional $33 million. To date, Twist Bioscience has ... "It is an exciting time to be leading Twist ... deliver industry-leading gene volume to our customers, enabling innovative ... Ph.D., CEO of Twist Bioscience. "We welcome the additional ...
(Date:3/27/2017)... March 27, 2017 Arena Pharmaceuticals, Inc. ... developing novel, small molecule drugs across multiple therapeutic areas, today ... Executive Officer, will present a corporate update at the 16th ... ET.  The conference will take place April 4-5, 2017 at ... York , NY.  A live audio ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... ... The Case Management Society of America (CMSA) will install six new members ... has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to serve on the ... position has also been added to the BOD, per an appointment made by CMSA ...
(Date:3/27/2017)... ... 2017 , ... EpiGentek , a Farmingdale, NY-based biotech ... methylation “gold rush” with their established portfolio of optimized assay kits that measure ... m6A , RNA methylation has received a new burst in interest as ...
(Date:3/27/2017)... Ranch, California (PRWEB) , ... March 27, 2017 , ... ... commitment to its customers. First National Capital has added 10 new sales professionals over ... grow its sales positions by 15 additional new hires over the course of 2017. ...
(Date:3/27/2017)... ... March 27, 2017 , ... From ... opioids alone responsible for over 33,000 of the 52,404 drug-related deaths in 2015.(2) ... (AB) 1512, which proposes a tax on prescription opioids to fund drug rehabilitation ...
(Date:3/25/2017)... (PRWEB) , ... March 25, 2017 , ... Norland at Swissray is pleased ... analyzers for large subjects. The ELITE DXA has an active scan window, which is ... or long to fit in the scan area could not undergo an accurate total body ...
Breaking Medicine News(10 mins):